Ionis (IONS) Stock Price Target Cut to $95 After Trial Results

Canaccord has reduced its price target for Ionis Pharmaceuticals (IONS) to $95 following the company's trial misses. The revision reflects concerns regarding Ionis's pipeline and potential future earnings performance. This adjustment may influence investor perception and stock performance, especially as the markets react to updated forecasts. Such price target changes can indicate underlying issues that affect stock valuation and investor sentiment.